Compare GE Vernova Inc (GEV) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? GE Vernova Inc trades at $982.86 (market cap $266.16B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.67 (market cap $58.74B). The key difference: GE Vernova Inc is far larger — about 4.5× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| GEV | TAK | |
|---|---|---|
Market Cap | $266.16B | $58.74B |
Volume | 2,324,165 | 3,110,994 |
Sector | Industrials | Health |
52-Week High | $1.17K | $19.05 |
52-Week Low | $547.96 | $13.23 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $255.83B | $86.65B |
Dividend Yield | 0.2% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent Q1 2026 earnings beat expectations with $17.44 EPS, though Q2 missed. The company secured the first US construction permit for its BWRX-300 SMR, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and execution challenges in the wind segment. The stock offers 27% upside to consensus target, supported by strong institutional sentiment and AI infrastructure tailwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
